Skip to main content

Fiat Chrysler said it knew nothing about the medical condition of Sergio Marchionne after a Swiss hospital said on Thursday it had been treating the deceased chief executive for more than a year.

“Due to medical privacy, the company had no knowledge of the facts relating to Mr. Marchionne’s health,” a Fiat Chrysler (FCA) spokesperson said.

Sergio Marchionne (File Photo)

Rebecca Cook

Questions have been raised about how long Mr. Marchionne, who died on Wednesday, was ill and how much the company knew before it made the situation public.

Story continues below advertisement

Mr. Marchionne rescued Fiat and Chrysler from bankruptcy after taking the wheel of the Italian car maker in 2004 and he multiplied Fiat’s value 11 times through 14 years of canny deal-making. He was due to step down at FCA in April next year.

“The company was made aware that Mr. Marchionne had undergone shoulder surgery and released a statement about this,” the spokesperson said.

“On Friday July 20, the Company was made aware with no detail by Mr. Marchionne’s family of the serious deterioration in Mr. Marchionne’s condition and that as a result he would be unable to return to work. The Company promptly took and announced the appropriate action the following day.”

The announcement of the death of Mr. Marchionne, 66, one of the auto industry’s most tenacious and respected CEOs, drew tributes from rivals and tears from his closest colleagues on Wednesday.

University Hospital Zurich said earlier on Thursday Mr. Marchionne had been having treatment for a serious illness for more than a year before his death.

Mr. Marchionne had fallen gravely ill after what the company had described as shoulder surgery at a Zurich hospital. He was replaced as CEO last weekend after Fiat Chrysler said his condition had worsened.

“Mr. Sergio Marchionne was a patient at USZ. Due to serious illness, he had been the recipient of recurring treatment for more than a year,” the hospital said in a statement.

Story continues below advertisement

“Although all the options offered by cutting-edge medicine were utilized, Mr. Marchionne unfortunately passed away.”

University Hospital Zurich declined to comment on Mr. Marchionne’s illness, but said it deeply regretted his death and expressed its condolences to his family.

Report an error
Tickers mentioned in this story
Unchecking box will stop auto data updates
Comments

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • All comments will be reviewed by one or more moderators before being posted to the site. This should only take a few moments.
  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed. Commenters who repeatedly violate community guidelines may be suspended, causing them to temporarily lose their ability to engage with comments.

Read our community guidelines here

Discussion loading ...

Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.
Cannabis pro newsletter